Atturos
Clinical diagnostics company spun out from University College Dublin developing targeted proteomic diagnostic tests. Core activities include targeted mass spectrometry assay development, biomarker discovery and validation, clinical assay transfer and in‑house validation, and machine‑learning analytics to produce clinically interpretable scores. The company operates a laboratory at the UCD Conway Institute and participates in multi‑partner European research consortia.
Industries
Nr. of Employees
small (1-50)
Products
RAPsA Dx
Serum protein diagnostic assay intended to discriminate patients with psoriatic arthritis from those with rheumatoid arthritis; performance data reported in peer‑reviewed publication(s).
OCPro Dx
Multi‑protein blood test designed to provide information on organ‑confined prostate cancer to support clinical decision making; early clinical data reported and commercialization planning ongoing.
PromarkerD
Blood test assessing risk of diabetic kidney disease in type 2 diabetes by measuring a panel of plasma biomarkers combined with clinical factors; method transferred to the company for local validation and European launch planning.
Atturos Targeted Proteomics Platform
An advanced clinical diagnostics platform using targeted mass spectrometry based measurements of blood proteins and machine learning analytics to support clinical treatment decisions.
RAPsA Dx
Serum protein diagnostic assay intended to discriminate patients with psoriatic arthritis from those with rheumatoid arthritis; performance data reported in peer‑reviewed publication(s).
OCPro Dx
Multi‑protein blood test designed to provide information on organ‑confined prostate cancer to support clinical decision making; early clinical data reported and commercialization planning ongoing.
PromarkerD
Blood test assessing risk of diabetic kidney disease in type 2 diabetes by measuring a panel of plasma biomarkers combined with clinical factors; method transferred to the company for local validation and European launch planning.
Atturos Targeted Proteomics Platform
An advanced clinical diagnostics platform using targeted mass spectrometry based measurements of blood proteins and machine learning analytics to support clinical treatment decisions.
Services
Design, optimisation and clinical validation of targeted multiplexed proteomic assays for blood biofluids; includes method transfer into the company laboratory.
Operational participation in multi‑partner EU and industry consortia to develop and evaluate biomarkers, sampling methods and in vitro testing approaches.
Design, optimisation and clinical validation of targeted multiplexed proteomic assays for blood biofluids; includes method transfer into the company laboratory.
Operational participation in multi‑partner EU and industry consortia to develop and evaluate biomarkers, sampling methods and in vitro testing approaches.
Expertise Areas
- Targeted proteomics and mass spectrometry
- Multiplexed proteomic assay development
- Biomarker discovery and clinical translation
- Clinical evaluation and validation of diagnostics
Key Technologies
- Targeted mass spectrometry (MRM)
- Immunoaffinity enrichment for proteomics
- Isotopically labelled internal standards
- Multiplexed protein assays
News & Updates
European patent filing (EP3084444) for prostate cancer biomarkers granted, supporting protection of the prostate cancer assay.
US patent granted covering prostate cancer biomarker claims associated with the prostate cancer assay.
Transfer of a multiplex immunoaffinity mass spectrometry method (PromarkerD) into the company for European validation and launch activities.
€1.57m Disruptive Technologies Innovation Fund award to a consortium led by the company for development of a plasma sampling device.
Participation in an IMI/industry‑funded consortium aimed at early identification and improved outcomes in psoriatic arthritis.
Presentation of candidate protein biomarkers to predict treatment response in psoriatic arthritis (GRAPPA‑Pfizer study).
European patent filing (EP3084444) for prostate cancer biomarkers granted, supporting protection of the prostate cancer assay.
US patent granted covering prostate cancer biomarker claims associated with the prostate cancer assay.
Transfer of a multiplex immunoaffinity mass spectrometry method (PromarkerD) into the company for European validation and launch activities.
€1.57m Disruptive Technologies Innovation Fund award to a consortium led by the company for development of a plasma sampling device.
Participation in an IMI/industry‑funded consortium aimed at early identification and improved outcomes in psoriatic arthritis.
Presentation of candidate protein biomarkers to predict treatment response in psoriatic arthritis (GRAPPA‑Pfizer study).